Acute lymphoblastic leukaemia trials in Italy

In Italy 35 Also abroad 563

35 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Asciminib Roll-over Study
Where
Genoa, Meldola, Milan, Pisa, Rome, Turin
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Milan, Rome, Turin
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 2/3Taking people
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Where
Bergamo, Bologna, Genoa, Rome, Turin
Age
12 years and over
People
340 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07570173 · EU 2025-522267-15-00
No phaseTaking people
Establishment of a Novel Flow Cytometric Diagnostic Assay to Effectively Evaluate Immune Reconstitution After Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia
Where
Monza, Padova
People
150 worldwide
Run by
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
See details and how to joinNCT07899840
Phase 3Taking people
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Where
Ancona, Bari, Bergamo, Bologna, Cagliari, Catania, Florence, Genoa, Monza, Naples, Padova, Palermo, Pavia, Rome, San Giovanni Rotondo, Trieste, Turin, Verona
Age
1 year to 64 years
People
750 worldwide
Run by
Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Bologna, Ravenna
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 1Taking people
Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
Where
Rome
Age
1 year to 35 years
People
24
Run by
Bambino Gesù Hospital and Research Institute
See details and how to joinNCT06080191
Phase 2/3Taking people
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Where
Roma
Age
3 months to 25 years
People
1,000 worldwide
Run by
Bambino Gesù Hospital and Research Institute
See details and how to joinNCT07297914 · EU 2025-522052-13-00
Phase 3Taking people
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Where
Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Catania, Cosenza, Florence, Genoa, Monza, Naples, Padova, Palermo, Parma, Pavia, Rome, Trieste, Turin, Verona
Age
1 day to 1 year
People
160 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00
Phase 3Taking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Brescia, Candiolo, Catania, Florence, Milan, Rome, Varese
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
Phase 1/2Taking people
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Where
Bergamo, Bologna, Meldola, Monza, Naples, Rome
Age
12 years and over
People
255 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137118 · EU 2023-505840-20-00
Phase 1/2Taking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Bologna, Brescia, Genova, Milan, Monza, Naples, Pavia, Rome, Torino
Age
1 year to 17 years
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Bologna, Meldola, Milan, Rome, Vicenza
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 1/2Not yet taking people in Italy
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
Where
Genoa, Monza, Rome
Age
Up to 64 years
People
22 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-522019-40-00 · EU 2025-522019-40-00
Phase 1/2Taking people
Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/Lymphoma
Where
Rome
Age
Up to 64 years
People
26
Run by
Ospedale Pediatrico Bambino Gesu'
See details and how to join2023-508355-39-00 · EU 2023-508355-39-00
Phase 2Taking people
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Where
Bologna, Catania, Genova, Monza, Naples, Padova, Palermo, Pavia, Rome, Torino, Trieste
Age
1 year to 17 years
People
100 worldwide
Run by
Pfizer
See details and how to joinNCT05748171 · EU 2023-509810-13-00
Phase 2/3Taking people
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Where
Monza, Pavia, Rome
Age
1 month to 18 years
People
1,800 worldwide
Run by
St. Anna Kinderkrebsforschung
See details and how to joinNCT01949129 · EU 2024-512657-24-00
No phaseTaking people
Novel Therapeutic Approach for Human T-cell Malignancies
Where
Naples, Padova
Age
18 years and over
People
120
Run by
Istituto Oncologico Veneto IRCCS
See details and how to joinNCT06600568
Phase 1/2Taking people
Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia
Where
Monza, Rome, Turin
Age
Up to 17 years
People
142 worldwide
Run by
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
See details and how to join2023-504694-20-00 · EU 2023-504694-20-00
Phase 1Taking people
Phase I clinical trial on the use of fresh, allogeneic, second-generation CD19-CAR T cells for treatment of children and young adult with relapsed/refractory B-cell Acute Lymphoblastic Leukemia
Where
Rome
Age
Up to 64 years
People
24
Run by
Ospedale Pediatrico Bambino Gesu'
See details and how to join2023-508420-36-00 · EU 2023-508420-36-00
Phase 3Taking people
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
Where
Ancona, Bari, Bergamo, Catania, Catanzaro, Cosenza, Florence, Genoa, Modena, Monza, Naples, Padova, Palermo, Parma, Perugia, Pescara, Rome, San Giovanni Rotondo, Trieste, Turin, Verona
Age
Up to 64 years
People
87 worldwide
Run by
Universita Degli Studi Di Milano Bicocca
See details and how to join2025-520982-39-00 · EU 2025-520982-39-00
No phaseTaking people
Bio-CAR-T BS Study
Where
Brescia
Age
18 years to 70 years
People
45
Run by
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
See details and how to joinNCT05366569
Phase 3Taking people
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Where
Bologna, Meldola, Milan, Monza, Ravenna, Rome, Turin, Varese
Age
18 years and over
People
350 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06051409 · EU 2024-511496-14-00
Phase 1/2Taking people
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Where
Bologna, Busto Arsizio, Genoa, Meldola, Padua, Perugia, Ravenna, Rome, Turin
Age
12 years and over
People
606 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555
Phase 2Taking people
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Where
Ancona, Bologna, Cagliari, Genoa, Monza, Naples, Palermo, Parma, Perugia, Rome, Trieste, Turin, Verona
Age
Up to 17 years
People
250 worldwide
Run by
Charite University, Berlin, Germany
See details and how to joinNCT03590171 · EU 2024-513070-21-00